<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03757871</url>
  </required_header>
  <id_info>
    <org_study_id>P171005J</org_study_id>
    <nct_id>NCT03757871</nct_id>
  </id_info>
  <brief_title>Contribution of Acupuncture on Pain Related to the Screening of Premature Retinopathy (ROP) by Digital Camera</brief_title>
  <acronym>ELAROP</acronym>
  <official_title>Contribution of Acupuncture on Pain Related to the Screening of Premature Retinopathy (ROP) by Digital Camera</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pain management in premature infants is essential because they are exposed to repeated minor
      painful procedures such as screening for premature retinopathy (ROP). Acupuncture has shown
      its analgesic effectiveness in many studies. Laser acupuncture is a simple, fast,
      side-effect-free method, but no study exists on the contribution of acupuncture in the
      management of pain caused by the examination of the fundus in addition to conventional
      therapies (suction, Glucose G30%, anaesthetic eye drops) which are not sufficiently
      effective.

      Hypothesis: Laser acupuncture is a medical device that would reduce the pain and discomfort
      of premature newborns when examining the fundus with a digital camera.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Randomized, single-centre, randomized, double-blind, randomized, controlled clinical trial in
      two parallel groups, acupuncture versus placebo as an add-on to the usual analgesic strategy
      (Glucose G 30%/suction and administration of a drop of anesthetic eye drops). The main
      objective is to evaluate the contribution of acupuncture versus placebo as an add-on to the
      G30% glucose solution 2 minutes before the examination associated with the instillation of a
      drop of oxybuprocaine administered 1 minute before the start of the examination on pain
      assessed at the first eye fundus (FO) by the score premature infant pain profile (PIPP)
      measured before the start of the examination (baseline) and on 30 seconds after the
      examination of both eyes.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 26, 2019</start_date>
  <completion_date type="Actual">March 1, 2020</completion_date>
  <primary_completion_date type="Actual">March 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>score at PIPP (premature infant pain profile) ≥ 10</measure>
    <time_frame>24 hours</time_frame>
    <description>Measurement of pain or discomfort defined by a PIPP score ≥ 10</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>pain and discomfort</measure>
    <time_frame>24 hours</time_frame>
    <description>Assess pain and discomfort (score FANS). The FANS score is a validated hetero-rating scale for assessing acute newborn pain when the face is difficult to analyse. On the 0 to 10 side, the absence of pain is defined by a score &lt; 3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>heart rate variability</measure>
    <time_frame>24 hours</time_frame>
    <description>assessment of heart rate variability (NIPE score)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Laser Stimulation</condition>
  <arm_group>
    <arm_group_label>Laser Stimulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>laser pen acupuncture projecting an infrared beam with a wavelength of 905nm bilaterally for 30 seconds on each point.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The placebo group will have an application of the pen according to the same extinguished laser criteria.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Laser stimulation</intervention_name>
    <description>an acupuncture or placebo session will be performed 30 minutes before the fundus examination. This session will last 5 minutes.</description>
    <arm_group_label>Laser Stimulation</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Premature from 23+0 to 30sa+6d regardless of birth weight with 1st FO for ROP
             screening;

          -  Premature birth weights &lt; 1250g with a 1st FO for ROP screening;

          -  Informed consent of the holder(s) of parental authority;

          -  Child benefiting from a social security system

        Exclusion Criteria:

          -  Analgesic or sedative drug treatment (benzodiazepines, morphine and related) within 48
             hours of the examination.

          -  Known chromosomal abnormality
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>23 Weeks</minimum_age>
    <maximum_age>31 Weeks</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Farnoux Caroline, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>APHP</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Biran Valerie, PHD</last_name>
    <role>Study Chair</role>
    <affiliation>APHP</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital Robert Debré</name>
      <address>
        <city>Paris</city>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>November 13, 2018</study_first_submitted>
  <study_first_submitted_qc>November 28, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 29, 2018</study_first_posted>
  <last_update_submitted>April 28, 2020</last_update_submitted>
  <last_update_submitted_qc>April 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinopathy of Prematurity</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

